Q-omics provides the consensus-scored RPL15P21 profile across patient tissues and cancer cell-line models. RPL15P21 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, RPL15P21 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, RPL15P21 RNA expression shows 11,485 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight UCS, COAD, and LUAD as cancer lineages where RPL15P21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL15P21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL15P21 survival associations across molecular data types. RPL15P21 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL15P21 RNA expression–survival associations across cancer types. High RPL15P21 expression shows unfavorable associations in LGG, but favorable associations in UCS, ACC, UVM, ESCA and KIRC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for RPL15P21 RNA expression.
This table summarizes RPL15P21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL15P21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL15P21 shows lower tumor expression in COAD, KIRC, HNSC, BRCA, READ and KIRP. The COAD box plot shows higher RPL15P21 RNA expression in normal versus tumor tissue (log2 FC = −1.272, t-test p < 0.001).
This table shows molecular features associated with RPL15P21 in patient tissues and cancer cell lines. In patient samples, RPL15P21 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
